Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan 7;12(1):e6588.
doi: 10.7759/cureus.6588.

A Case of Kratom-induced Seizures

Affiliations
Case Reports

A Case of Kratom-induced Seizures

Hasnain Afzal et al. Cureus. .

Abstract

Kratom or Mitragna speciosa is a tropical tree that is indigenous to Southeast Asia, where it has been used for various medicinal reasons. In the West, it is used in the self-treatment of opioid withdrawal, pain, and a variety of mood and anxiety states. Two active ingredients in kratom are mitragynine and 7-hydroxymitragynine, which have affinity at the mu-opioid receptor among others. Kratom is easily available over the Internet and its use is increasing in the United States. It is currently listed by the Drug Enforcement Administration as a drug of concern. In 2017, the U.S. Food and Drug Administration started issuing a series of warnings about kratom, and by early 2018, it released a statement identifying 44 deaths related to kratom use. The Centers for Disease Control and Prevention has also reported 91 deaths directly linked to kratom use in 2019. Although its safety profile needs additional research for clarification, there have been reports of kratom-induced or kratom-related respiratory depression, hypothyroidism, secondary hypogonadism, hyperprolactinemia, psychosis, and seizures. We report a case of kratom-induced tonic-clonic seizures in a 27-year-old Caucasian male with a psychiatric history of anxiety, attention-deficit/hyperactivity disorder, benzodiazepine use disorder, and opioid use disorder. He was hospitalized after a witnessed tonic-clonic seizure. There was no significant metabolic abnormality on laboratory testing. Spinal cord and brain imaging were unremarkable, whereas his urine toxicology was positive for opioids only, which was likely a false-positive result due to cross-reactivity with his sleeping aids. He was evaluated by the Consultation-Liaison Psychiatry team for psychotic symptoms. On evaluation, the patient's psychosis had resolved, but he endorsed racing thoughts, significant anxiety, and insomnia. He admitted to drinking three to four 8-mL bottles of Kratom daily for one-and-a-half years to self-medicate his anxiety after losing his health insurance. In the hospital, he was treated with anxiolytics, counseled to abstain from Kratom use, and was referred for substance use disorder treatment. This case highlights the life-threatening complications of Kratom that is easily available online.

Keywords: kratom; opioid; seizures; substance use.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Images of kratom products that can be purchased at a “smoke shop” in the US: (A) chopped leaves, which are typically brewed into “kratom tea”, (B) capsules containing finely chopped leaves, and (C) compressed tablets containing leaves or resin.
Figure 2
Figure 2. Mitragynine – molecular formula: C23H30N2O4; molecular weight: 398.50 g/mol.
Figure 3
Figure 3. 7-hydroxymitragynine – molecular formula: C23H30N2O5; molecular weight: 414.50 g/mol.
Figure 4
Figure 4. Yohimbine – molecular formula: C21H26N2O3; molecular weight: 354.4 g/mol.
Figure 5
Figure 5. Serotonin (5-hydroxytryptamine) – molecular formula: C10H12N2O; molecular weight: 176.21 g/mol.
.

References

    1. National Center for Biotechnology Information. PubChem Database. Mitragynine. [Nov;2019 ];https://pubchem.ncbi.nlm.nih.gov/compound/Mitragynine
    1. Pharmacologic and clinical assessment of kratom. Michael White C. Am J Health Syst Pharm. 2018;75:261–267. - PubMed
    1. Kratom: a dangerous player in the opioid crisis. [Jan;2020 ];Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. J Community Hosp Intern Med Perspect. 2018 8:107–110. - PMC - PubMed
    1. Treatment of kratom dependence with buprenorphine-naloxone maintenance. Buresh M. J Addict Med. 2018;12:481–483. - PubMed
    1. Recurrent seizures from chronic kratom use, an atypical herbal opioid. [Jan;2020 ];Tatum WO, Hasan TF, Coonan EE, Smelick CP. Epilepsy Behav Case Rep. 2018 10:18–20. - PMC - PubMed

Publication types

LinkOut - more resources